Table 1 of Strzalka-Mrozik, Mol Vis 2010; 16:1272-1279. Table 1 of Strzalka-Mrozik, Mol Vis 2010; 16:1272-1279.
Table 1. Selected clinical features and biochemical markers of type 2 diabetus mellitus (DM) patients and controls
| Characteristic | Type 2 DM (n=58) | Controls (n=60) |
|---|---|---|
| Gender | ||
| M | 21 | 33 |
| F | 37 | 27 |
| Age (year) | 60.0 (42.0–83.0) | 61.0 (52.0–76.0) |
| BMI (kg/m2) | 29.4 (22.0–44.0) | 27.0 (21.0–32.0) |
| BMI | ||
| Normal | 9 | 24 |
| Overweight | 23 | 24 |
| Obese | 26 | 12 |
| Smoking | ||
| Yes | 6 | 0 |
| No | 52 | 60 |
| Arterial hypertension | ||
| Yes | 40 | 4 |
| No | 18 | 56 |
| *Glycemia | 142.5 (69.0–387.0) | 100.0 (89.0–108.0) |
| *Serum creatinine | 0.9 (0.5–1.1) | 1.2 (0.9–1.1) |
| *Total cholesterol | 193.0 (139.0–326.0) | 220.0 (184.0–267.0) |
| *Triglycerides | 158.0 (69.0–343.0) | 110.0 (86.0–193.0) |
| *HDL cholesterol | 49.5 (40.0–64.0) | 65.0 (47.0–128.0) |
| *LDL cholesterol | 125.5 (100.0–20.0) | 147.0 (52.0–199.0) |
| Glycosylated hemoglobin (%) | 7.5 (5.3–9.8) | - |
| Length of clinical course (year) | 10.5 (1.0–29.0) | - |
| Type of retinopathy | ||
| No DR | 19 | - |
| NPDR | 28 | - |
| PDR | 11 | - |
| Diabetic macular edema | ||
| Yes | 0 | - |
| No | 58 | - |
| Frequency of glycemic control | ||
| Less than once daily | 14 | - |
| Once daily | 14 | - |
| Twice daily | 13 | - |
| Thrice daily | 17 | - |
| Insulin therapy | ||
| Yes | 31 | - |
| No | 27 | - |
| Length of insulin therapy (years) | 7.0 (0–25.0) | - |
| Medication with oral anti-diabetic drugs | ||
| Yes | 44 | - |
| No | 14 | - |
| Type of the anti-diabetic drug | ||
| Metformin | 36 | - |
| Sulfonylureas | 24 | - |
| Alpha-glucosidase inhibitor | 6 | - |
| Type of anti-hypertensive drug | ||
| β-blocker | 13 | - |
| Ca-blocker | 11 | - |
| ACE inhibitor | 29 | - |
| Diuretics | 12 | - |